Norway
· Delayed Price · Currency is NOK BerGenBio ASA Statistics
Total Valuation
BerGenBio ASA has a market cap or net worth of NOK 71.04 million. The enterprise value is -68.29 million.
| Market Cap | 71.04M |
| Enterprise Value | -68.29M |
Important Dates
The next estimated earnings date is Tuesday, April 29, 2025.
| Earnings Date | Apr 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BerGenBio ASA has 39.09 million shares outstanding. The number of shares has increased by 146.47% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 39.09M |
| Shares Change (YoY) | +146.47% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.86% |
| Owned by Institutions (%) | 7.50% |
| Float | 22.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 75.61 |
| PB Ratio | 0.58 |
| P/TBV Ratio | 0.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.49 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.79, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.79 |
| Quick Ratio | 4.62 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -32.18 |
Financial Efficiency
Return on equity (ROE) is -111.35% and return on invested capital (ROIC) is -75.19%.
| Return on Equity (ROE) | -111.35% |
| Return on Assets (ROA) | -57.26% |
| Return on Invested Capital (ROIC) | -75.19% |
| Return on Capital Employed (ROCE) | -122.44% |
| Revenue Per Employee | 56,533 |
| Profits Per Employee | -9.29M |
| Employee Count | 15 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.63% in the last 52 weeks. The beta is 1.77, so BerGenBio ASA's price volatility has been higher than the market average.
| Beta (5Y) | 1.77 |
| 52-Week Price Change | -90.63% |
| 50-Day Moving Average | 4.90 |
| 200-Day Moving Average | 8.84 |
| Relative Strength Index (RSI) | 34.53 |
| Average Volume (20 Days) | 927,065 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BerGenBio ASA had revenue of NOK 848,000 and -139.28 million in losses. Loss per share was -3.95.
| Revenue | 848,000 |
| Gross Profit | 848,000 |
| Operating Income | -151.23M |
| Pretax Income | -139.28M |
| Net Income | -139.28M |
| EBITDA | -150.78M |
| EBIT | -151.23M |
| Loss Per Share | -3.95 |
Balance Sheet
The company has 140.16 million in cash and 818,000 in debt, giving a net cash position of 139.34 million or 3.56 per share.
| Cash & Cash Equivalents | 140.16M |
| Total Debt | 818,000 |
| Net Cash | 139.34M |
| Net Cash Per Share | 3.56 |
| Equity (Book Value) | 122.70M |
| Book Value Per Share | 3.14 |
| Working Capital | 122.27M |
Cash Flow
| Operating Cash Flow | -153.24M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -17,834.08% |
| Pretax Margin | -16,424.76% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BerGenBio ASA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -146.47% |
| Shareholder Yield | -146.47% |
| Earnings Yield | -196.05% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on May 30, 2024. It was a reverse split with a ratio of 0.01.
| Last Split Date | May 30, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
BerGenBio ASA has an Altman Z-Score of 6.83.
| Altman Z-Score | 6.83 |
| Piotroski F-Score | n/a |